X4 Pharmaceuticals (NASDAQ:XFOR) CFO David Kirske Sells 8,543 Shares

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO David Kirske sold 8,543 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total value of $36,393.18. Following the completion of the sale, the chief financial officer owned 167,750 shares of the company’s stock, valued at $714,615. The trade was a 4.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

X4 Pharmaceuticals Price Performance

NASDAQ XFOR traded down $0.58 on Wednesday, reaching $4.09. 806,979 shares of the company’s stock traded hands, compared to its average volume of 536,639. X4 Pharmaceuticals, Inc. has a 12 month low of $1.35 and a 12 month high of $4.83. The company has a debt-to-equity ratio of 0.45, a current ratio of 10.18 and a quick ratio of 9.98. The stock has a 50-day simple moving average of $4.09 and a 200 day simple moving average of $3.93. The stock has a market cap of $385.77 million, a PE ratio of -0.90 and a beta of 0.34.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The firm had revenue of $2.71 million for the quarter, compared to the consensus estimate of $3.20 million. As a group, research analysts predict that X4 Pharmaceuticals, Inc. will post -0.77 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on XFOR shares. Leerink Partners began coverage on shares of X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price target for the company. Guggenheim began coverage on X4 Pharmaceuticals in a report on Monday, March 9th. They issued a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings raised X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Finally, Wall Street Zen upgraded X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, X4 Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.38.

Institutional Investors Weigh In On X4 Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kingdon Capital Management L.L.C. grew its holdings in X4 Pharmaceuticals by 300.0% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 933,332 shares of the company’s stock worth $3,192,000 after acquiring an additional 700,000 shares during the last quarter. Rosalind Advisors Inc. bought a new position in shares of X4 Pharmaceuticals during the third quarter valued at about $5,283,000. Perceptive Advisors LLC bought a new position in shares of X4 Pharmaceuticals during the fourth quarter valued at about $25,258,000. Empery Asset Management LP purchased a new stake in shares of X4 Pharmaceuticals during the fourth quarter worth about $35,804,000. Finally, Jefferies Financial Group Inc. bought a new stake in shares of X4 Pharmaceuticals in the fourth quarter worth about $104,000. 72.03% of the stock is currently owned by institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.